Learn More
BACKGROUND We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC). PATIENTS AND METHODS A total of 379(More)
1006 Background: The addition of bevacizumab (Bev) to EC-docetaxel chemotherapy (CT) did not improve pathological complete response (pCR) rates in unselected patients (P) with HER2 negative breast(More)